Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Recruiting · Phase 2 · NCT06824168
Conditions: Acute Myeloid Leukemia, Leukemia
At a glance
- Research payments reported, 2025
- $38,467
- U.S. investigators named
- 2
- Sites paid
- 3
- Planned or actual enrollment
- 130
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- Quizartinib High Dose (drug), Quizartinib Low Dose (drug)
- Dates
- Started 2025-07-18; completion 2032-07-14
- Results posted
- Not yet
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
From ClinicalTrials.gov, last updated 2026-09-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $38,467 in research payments for this study in 2025 (12 payments).
Products named: Vanflyta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Shilpan S. Shah, MD Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Research Alliance $26,684
- The Methodist Hospital Research Institute $11,412
- Houston Methodist Hospital, TX $371
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.